🎉 M&A multiples are live!
Check it out!

Public Comps and Valuation Multiples
for BioTech

Benchmark revenue and EBITDA valuation multiples for public comps like Gilead Sciences, Sanofi, Novo Nordisk, Vertex Pharmaceuticals and AbbVie.

BioTech

See analyst estimates and all valuation multiples for BioTech
Company EV EV/Revenue EV/EBITDA
$708B 14.4x 36.9x
$384B 4.3x 12.1x
$378B 6.6x 14.7x
$290B 6.5x 13.3x
$153B 6.4x 20.2x
$148B 5.1x 12.4x
$145B 3.0x 14.9x
$131B 2.7x 9.3x
$123B 10.9x 56.9x
$84.6B 2.1x 5.9x
$82.9B 5.4x 16.3x
$72.0B 7.8x 18.2x
$56.3B 1.1x 5.3x
$8.3B 2.6x 7.4x
$7.1B 9.4x 36.3x
$6.7B 9.1x n/a
$5.7B n/a n/a
$5.2B 11.8x 38.8x
$4.7B 5.7x 21.3x
$4.5B 182.6x -7.9x
$3.5B 16.1x -397.7x
$1.8B 1.8x 9.0x
$1.6B 37.8x -3.8x
$1.6B 2.3x 3.8x
$1.5B 1.3x 4.1x
$1.5B 614.6x -4.1x
$1.4B 1.7x 5.7x
$1.2B 2.0x 6.9x
$1.1B 127.0x -2.4x
$1.1B 0.9x 2.7x
$1.1B n/a n/a
$960M 3.3x 22.4x
$932M n/a -6.0x
$855M 21.0x -175.1x
$815M 2.4x 28.3x
$747M n/a n/a
$692M 1.0x 3.7x
$613M n/a n/a
$585M 1.3x 6.0x
$550M n/a n/a
$462M n/a -1.3x
$414M 6.0x n/a
$362M n/a -1.7x
$354M n/a n/a
$329M 7.0x -4.9x
$327M 60.0x n/a
$315M 30.3x -1.9x
$307M 1.0x 5.8x
$300M 1.2x 6.3x
$291M 44.7x -3.4x
$279M 7.7x -9.8x
$257M 1.2x -2.2x
$240M 113.0x -15.8x
$233M n/a n/a
$227M n/a -0.6x
$203M 1.4x -1.0x
$177M 2.9x -3.8x
$167M 15.0x n/a
$167M 5.9x -0.8x
$155M n/a -4.4x
$152M 0.3x 1.1x
$138M 4.8x n/a
$130M 1.3x 5.1x
$118M 186.8x -1.9x
$110M 0.9x 22.6x
$108M n/a -3.6x
$107M n/a n/a
$102M 84.1x -4.4x
$95.8M n/a n/a
$95.4M 163.0x n/a
$50.9M n/a n/a
$41.1M 8.2x -5.0x
$38.5M 1.5x n/a
$35.3M 4.4x n/a
$19.2M 5.2x n/a
$18.1M 23.5x -9.5x
$13.0M 7.8x n/a
$12.7M n/a n/a
$11.5M 23.9x n/a
$3.3M 0.5x -0.1x
-$3.5M -0.3x 0.1x
-$6.5M -0.3x n/a
-$17.5M n/a n/a
-$19.5M -36.9x 0.3x
-$25.8M n/a n/a
-$42.7M -0.3x -1.8x
-$43.5M -1.4x 1.3x
-$56.4M n/a n/a
-$57.5M -3.1x n/a
-$58.7M n/a n/a
-$74.9M -130.1x n/a
-$95.3M -55.2x 1.7x
-$105M n/a 0.6x
-$109M -11.1x 0.6x
-$222M n/a 0.8x
-$272M -237.3x 1.4x

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.